Figure 1 (Abecma 01)
Abecma Suspension
Product Images NDC 59572-515
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Abecma (NDC 59572-515). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Celgene Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Principal Display Panel (30 mL Bag Label)
Idecabtagene vicleucel is a genetically modified suspension of autologous T cells used for intravenous use only. The acceptable volume is 10-30mL per bag. The dose may be suspended in one or more infusion bags. It contains CAR-positive T cells in cryopreservative solution with DMSO USP. Do not use a leukodepleting filter or irradiate. It is not evaluated for infectious substances and preservative-free. It is to be stored in the vapor phase of liquid nitrogen. The description also includes contact information for the manufacturers. No information is provided on the purpose or use of Idecabtagene vicleucel.*
Principal Display Panel (30 mL Cassette Label)
TAbecma is a suspension of genetically modified autologous T cells that is used intravenously. The dosage and acceptable volume depend on the prescribing information, and it is not to be used with a leukodeplefing filter or irradiated. The suspension contains 300 to 460 x 10¢ anti-BCMAO2 CAR-positive T cells and should be stored in the vapor phase of liquid nitrogen (< -130°C). It is manufactured by Celgene Corporation, a Bristol-Myers Squibb Company, and has no preservatives. Patient information, including name, date of birth, DIN/Aph ID, bag ID, and lot and expiration dates, is also included.*
Principal Display Panel (70 mL Bag Label)
This is a description of a medication called idecabtagene vicleucel. It is a genetically modified treatment that uses a patient's own immune T-cells to fight certain types of cancer. The medication is only for autologous and intravenous use and contains a specific number of anti-BCMA02 CAR-positive T-cells in a 5% DMSO USP solution. The dosage for the treatment is available on the prescribing information and Release for Infusion Certificate. The medication is preservative-free and should be stored in the vapor phase of liquid nitrogen at less than -130°C.*
Principal Display Panel (70 mL Cassette Label)
This is a description of a drug called idecabtagene vicleucel, trade name TAbecma. It is a genetically modified autologous T cell used for intravenous use. The dosage is mentioned and prescribing information is available. The drug contains 300 to 460 x 10 anti-BCMAO2 CAR-positive T cells in cryopreservative solution containing 5% DMSO USP, and dose may be suspended in one or more infusion bags. It is advised not to use a leukodepleting filter or irradiate it. There is no evaluation available for infectious substances, and it is preservative-free. The drug needs to be stored in the vapor phase of liquid nitrogen (< -130°C). The information about manufacturing and company contact information is also available. Personal details and product information like bag ID, join percentage, lot number, and expiration date are given.*
Principal Display Panel (100 mL Bag Label)
Abecma is a suspension of genetically modified autologous T cells for autologous and intravenous use only. The acceptable volume for infusion is 55mL - 100mL per bag, with dosage information available in the prescribing information and Bristol-Myers Squibb Company Release for Infusion Certificate. Each bag of Abecma contains 300 to 460 x 10° anti-BCMAO2 US License No. 2252 CAR-positive T cells in cryopreservative solution with 5% DMSO USP. The dose may be suspended in one or more infusion bags. Abecma should not be used with a leukodepleting filter or irradiate, is not evaluated for infectious substances, and is preservative-free. Abecma should be stored in the vapor phase of liquid nitrogen.*
Principal Display Panel (100 mL Cassette Label)
This is a description of a prescription drug called idecabtagene vicleucel, marketed as TAbecma. The drug is indicated for autologous and intravenous use only, and is a suspension for IV infusion. It contains genetically modified autologous T cells that are anti-BCMAO2 CAR-positive. The drug does not contain preservatives and must be stored in the vapor phase of liquid nitrogen (<-130°C). The drug has not been evaluated for infectious substances. The dosage should be determined based on the prescribing information and release for Infusion Certificate available with the shipment. The manufacturer is Celgene Corporation, a Bristol-Myers Squibb Company, located in Summif, New Jersey. The drug is identified by the NDC code 59572-515-03, and it should not be used with a leukodepleting filter or irradiated. Patient information like name, date of birth, DIN/Aph ID, and bag ID is also included in the description.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
